Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
Groheux D, Hatt M, Hindié E, Giacchetti S, de Cremoux P, Lehmann-Che J, Martineau A, Marty M, Cuvier C, Cheze-Le Rest C, de Roquancourt A, Visvikis D, Espié M. Groheux D, et al. Among authors: de cremoux p, de roquancourt a. Cancer. 2013 Jun 1;119(11):1960-8. doi: 10.1002/cncr.28020. Epub 2013 Mar 15. Cancer. 2013. PMID: 23504954 Free article.
Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D, Hindié E, Giacchetti S, Hamy AS, Berger F, Merlet P, de Roquancourt A, de Cremoux P, Marty M, Hatt M, Espié M. Groheux D, et al. Among authors: de cremoux p, de roquancourt a. Eur J Cancer. 2014 Jul;50(11):1864-71. doi: 10.1016/j.ejca.2014.04.020. Epub 2014 May 16. Eur J Cancer. 2014. PMID: 24841218
Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
Groheux D, Sanna A, Majdoub M, de Cremoux P, Giacchetti S, Teixeira L, Espié M, Merlet P, de Roquancourt A, Visvikis D, Hatt M, Resche-Rigon M, Hindié E. Groheux D, et al. Among authors: de cremoux p, de roquancourt a. J Nucl Med. 2015 Jun;56(6):824-31. doi: 10.2967/jnumed.115.154138. Epub 2015 Apr 16. J Nucl Med. 2015. PMID: 25883123 Free article.
¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
Groheux D, Biard L, Giacchetti S, Teixeira L, Hindié E, Cuvier C, Vercellino L, Merlet P, de Roquancourt A, de Cremoux P, Resche-Rigon M, Espié M. Groheux D, et al. Among authors: de cremoux p, de roquancourt a. J Nucl Med. 2016 Apr;57(4):536-43. doi: 10.2967/jnumed.115.163907. Epub 2015 Dec 23. J Nucl Med. 2016. PMID: 26697967 Free article.
18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis.
Groheux D, Martineau A, Teixeira L, Espié M, de Cremoux P, Bertheau P, Merlet P, Lemarignier C. Groheux D, et al. Among authors: de cremoux p. Breast Cancer Res. 2017 Jan 5;19(1):3. doi: 10.1186/s13058-016-0793-2. Breast Cancer Res. 2017. PMID: 28057031 Free PMC article.
Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D, Biard L, Lehmann-Che J, Teixeira L, Bouhidel FA, Poirot B, Bertheau P, Merlet P, Espié M, Resche-Rigon M, Sotiriou C, de Cremoux P. Groheux D, et al. Among authors: de cremoux p. Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1279-1288. doi: 10.1007/s00259-018-3998-z. Epub 2018 Apr 4. Eur J Nucl Med Mol Imaging. 2018. PMID: 29616304
p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, Espié M, de Thé H. Bertheau P, et al. Among authors: de the h, de cremoux p, de roquancourt a. Breast. 2013 Aug;22 Suppl 2:S27-9. doi: 10.1016/j.breast.2013.07.005. Breast. 2013. PMID: 24074787 Free article. Review.
18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients.
de Cremoux P, Biard L, Poirot B, Bertheau P, Teixeira L, Lehmann-Che J, Bouhidel FA, Merlet P, Espié M, Resche-Rigon M, Sotiriou C, Groheux D. de Cremoux P, et al. Oncotarget. 2018 Mar 27;9(23):16343-16353. doi: 10.18632/oncotarget.24674. eCollection 2018 Mar 27. Oncotarget. 2018. PMID: 29662649 Free PMC article.
168 results